Givaudan eyes growth in Brazil
This article was originally published in The Rose Sheet
Executive SummarySwiss flavor and fragrance firm unveiled its five-year plan in Zurich Aug 31, indicating that developing markets will play an increasing role in corporate growth. Givaudan expects Brazil to be largest-value market for fine fragrance by 2014, outpacing the U.S., based on Euromonitor data. Company recently opened a Creative Center in Brazil and plans to expand its creative resources elsewhere in Latin America. Developing markets currently account for 41% of Givaudan's overall sales and are expected to contribute 50% of sales by 2015. Revenue for the first half of 2010 rose 10.5% compared with the prior-year period, driven by sales of consumer products and increased flavors sales in Latin America, Givaudan says. Firm's overall objective is to grow organically between 4.5% and 5.5% annually, based on assumed market growth of 2% to 3%, and to continue our path of market share gain over the next five years," CEO Gilles Andrier states in a company release
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.